BSD Medical Receives FDA Clearance to Market the MicroThermX-100 Microwave Ablation System

SALT LAKE CITY, Sept. 11, 2008 (GLOBE NEWSWIRE) -- BSD Medical Corporation (Nasdaq:BSDM), a leading developer of microwave systems that are used primarily in the treatment of cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted the company a 510(k) clearance to market its MicroThermX(r)-100 Microwave Ablation System (MTX-100). Clearance from the FDA of BSD Medical's 510(k) Premarket Notification submission authorizes the commercial sale of the MTX-100 in the United States.

Back to news